RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models.
Saved in:
| Title: | RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models. |
|---|---|
| Authors: | Grether U; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Foxton RH; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Gruener S; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Korn C; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Kimbara A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Osterwald A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Zirwes E; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Uhles S; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Thoele J; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Colé N; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Rogers-Evans M; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Röver S; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Nettekoven M; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Martin RE; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Adam JM; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Fingerle J; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Bissantz C; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Guba W; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Alker A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Szczesniak AM; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada., Porter RF; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada., Toguri TJ; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada., Revelant F; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Poirier A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Perret C; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Winther L; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Caruso A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Fezza F; Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy., Maccarrone M; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.; European Center for Brain Research (CERC), Santa Lucia Foundation IRCCS, Rome, Italy., Kelly MEM; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada., Fauser S; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Ullmer C; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2024 Jul 12; Vol. 15, pp. 1426446. Date of Electronic Publication: 2024 Jul 12 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39070793 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Grether+U%22">Grether U</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Foxton+RH%22">Foxton RH</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Gruener+S%22">Gruener S</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Korn+C%22">Korn C</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kimbara+A%22">Kimbara A</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Osterwald+A%22">Osterwald A</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Zirwes+E%22">Zirwes E</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Uhles+S%22">Uhles S</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Thoele+J%22">Thoele J</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Colé+N%22">Colé N</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Rogers-Evans+M%22">Rogers-Evans M</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Röver+S%22">Röver S</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Nettekoven+M%22">Nettekoven M</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Martin+RE%22">Martin RE</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Adam+JM%22">Adam JM</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Fingerle+J%22">Fingerle J</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bissantz+C%22">Bissantz C</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Guba+W%22">Guba W</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Alker+A%22">Alker A</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Szczesniak+AM%22">Szczesniak AM</searchLink>; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada.<br /><searchLink fieldCode="AU" term="%22Porter+RF%22">Porter RF</searchLink>; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada.<br /><searchLink fieldCode="AU" term="%22Toguri+TJ%22">Toguri TJ</searchLink>; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada.<br /><searchLink fieldCode="AU" term="%22Revelant+F%22">Revelant F</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Poirier+A%22">Poirier A</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Perret+C%22">Perret C</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Winther+L%22">Winther L</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Caruso+A%22">Caruso A</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Fezza+F%22">Fezza F</searchLink>; Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Maccarrone+M%22">Maccarrone M</searchLink>; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.; European Center for Brain Research (CERC), Santa Lucia Foundation IRCCS, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Kelly+MEM%22">Kelly MEM</searchLink>; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada.<br /><searchLink fieldCode="AU" term="%22Fauser+S%22">Fauser S</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Ullmer+C%22">Ullmer C</searchLink>; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101548923%22">Frontiers in pharmacology</searchLink> [Front Pharmacol] 2024 Jul 12; Vol. 15, pp. 1426446. <i>Date of Electronic Publication: </i>2024 Jul 12 (<i>Print Publication: </i>2024). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Media]%22">Frontiers Media] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101548923 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1663-9812 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216639812%22">16639812 </searchLink><i>NLM ISO Abbreviation: </i>Front Pharmacol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39070793 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fphar.2024.1426446 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1426446 Titles: – TitleFull: RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Grether U – PersonEntity: Name: NameFull: Foxton RH – PersonEntity: Name: NameFull: Gruener S – PersonEntity: Name: NameFull: Korn C – PersonEntity: Name: NameFull: Kimbara A – PersonEntity: Name: NameFull: Osterwald A – PersonEntity: Name: NameFull: Zirwes E – PersonEntity: Name: NameFull: Uhles S – PersonEntity: Name: NameFull: Thoele J – PersonEntity: Name: NameFull: Colé N – PersonEntity: Name: NameFull: Rogers-Evans M – PersonEntity: Name: NameFull: Röver S – PersonEntity: Name: NameFull: Nettekoven M – PersonEntity: Name: NameFull: Martin RE – PersonEntity: Name: NameFull: Adam JM – PersonEntity: Name: NameFull: Fingerle J – PersonEntity: Name: NameFull: Bissantz C – PersonEntity: Name: NameFull: Guba W – PersonEntity: Name: NameFull: Alker A – PersonEntity: Name: NameFull: Szczesniak AM – PersonEntity: Name: NameFull: Porter RF – PersonEntity: Name: NameFull: Toguri TJ – PersonEntity: Name: NameFull: Revelant F – PersonEntity: Name: NameFull: Poirier A – PersonEntity: Name: NameFull: Perret C – PersonEntity: Name: NameFull: Winther L – PersonEntity: Name: NameFull: Caruso A – PersonEntity: Name: NameFull: Fezza F – PersonEntity: Name: NameFull: Maccarrone M – PersonEntity: Name: NameFull: Kelly MEM – PersonEntity: Name: NameFull: Fauser S – PersonEntity: Name: NameFull: Ullmer C IsPartOfRelationships: – BibEntity: Dates: – D: 12 M: 07 Text: 2024 Jul 12 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 1663-9812 Numbering: – Type: volume Value: 15 Titles: – TitleFull: Frontiers in pharmacology Type: main |
| ResultId | 1 |
